EN PL
ORIGINAL PAPER
The concentration and microheterogeneity of acute-phase proteins in patients with systemic sclerosis
 
More details
Hide details
 
Online publication date: 2010-12-20
 
 
Reumatologia 2010;48(6):416-420
 
KEYWORDS
ABSTRACT
The concentration and microheterogeneity of acute-phase proteins (APP) differ in acute and chronic types of inflammation. The qualitative changes of some acute-phase glycoproteins are referred to as major microheterogeneity. Affinity electrophoresis with a lectin, concanavalin A (ConA), as a ligand has been successfully used to determine acute-phase glycoproteins microheterogeneity. The concentration and microheterogeneity of acute-phase proteins can be used in early diagnosis, management and prognosis of chronic inflammatory stages including Systemic Sclerosis (SS). The study included 45 patients with SS with a mean age of 46.2 years. All patients fulfilled the American Rheumatism Association revised criteria for classification of SS. The control group comprised 15 healthy individuals with a mean age of 42.3 years. Serum levels of acid-glycoprotein (AGP), antichymotrypsin (ACT) and ceruloplasmin (CP) were measured by electroimmunoassay using anti-AGP, anti-ACT and anti-CP antibodies. The level of C-reactive protein (CRP) was determined by radial immunodiffusion with anti-CRP antibodies. The microheterogeneity of the acute-phase proteins was assessed by agarose affinity electrophoresis using Con A as a ligand, as described by Bøg-Hansen. The increased concentration of only a few proteins (AGP, CRP, CP) was found. A moderate rise of CRP, CP and AGP levels in about 50% of SS cases was associated with arthritis and cutaneous ulcers. High levels of proteins were observed in a group with pulmonary and heart involvement. Microheterogeneity of acute-phase proteins was changed in studied patients and showed different pictures. Our results support the changed acute-phase response in patients with systemic sclerosis.
REFERENCES (19)
1.
Carpentier PH, Maricq HR. Microvasculature in systemic sclerosis. Rheum Dis Clin North Am 1990; 16: 75-91.  .
 
2.
Boyd RL, Wilson TJ, Van De Water J, et al. Selective abnormalities in the thymic microenvironment associated with avian scleroderma, an inherited fibrotic disease of L200 chickens. J Autoimmun 1991; 4: 369-80.  .
 
3.
Furst DE. The endothelium in the pathogenesis of systemic sclerosis: is it primary or secondary? [editorial]. J Mal Vasc 1999; 24: 95-98.  .
 
4.
Chen ZY, Silver RM, Ainsworth SK, et al. Association between fluorescent antinuclear antibodies, capillary patterns, and clinical features in scleroderma spectrum disorders. Am J Med 1984; 77: 812-822.  .
 
5.
Volanakis JE. Acute-phase proteins in rheumatic diseases. In: Arthritis and allied conditions, Koopman WJ (ed.). Williams&Wilkins, Baltimore 1997; 505-514.  .
 
6.
LeRoy EC, Medsger TA Jr. Criteria for the classification of early systemic sclerosis. J Rheumatol 2001; 28: 1573-1576 .  .
 
7.
Laurell CB. Quantitative estimation of proteins by electrophoresis in agarose gel containing antibodies. Anal Biochem 1966; 15: 45-49.  .
 
8.
Hansen JS, et al. Electrophoretic analysis of the glycan microheterogeneity of orosomucoid in cancer and inflammation. Electrophoresis 1986; 7: 180-192.  .
 
9.
Systemic sclerosis (textbook), Clements PhJ, Furst DE (eds). Williams&Wilkins, Baltimore 1996. .
 
10.
White B. Immunopathogenesis of systemic sclerosis. Rheum Dis Clin North Am 1996; 22: 695-708. .
 
11.
Chizzolini C. T lymphocyte and fibroblast interactions: the case of skin involvement in systemic sclerosis and other examples. Springer Semin Immunopathol 1999; 21: 431-450. .
 
12.
Sakkas LI, Xu B, Artlett CM, et al. Oligoclonal T cell expansion in the skin of patients with systemic sclerosis. J Immunol 2002; 168: 3649-3659. .
 
13.
Postlethwaite AE. Role of T cells and cytokines in effecting fibrosis. Int Rev Immunol 1995; 12: 247-258. .
 
14.
Marra R, Pagano L, Storti S, et al. Evaluation of some inflammatory, coagulative and immune parameters in progressive systemic sclerosis. Acta Med Pol 1988; 29: 81-88. .
 
15.
Seibold JR, Iammarino RM, Rodman GP. Alpha-1-antitrypsin in progressive systemic sclerosis. Arthritis Rheum 1980; 23: 367-370. .
 
16.
Becvar R, Stork J, Pesakova V, et al. Clinical correlations of potential activity markers in systemic sclerosis. Ann N Y Acad Sci 2005; 1051: 404-412. .
 
17.
Avouac J, Walker U, Tyndall A, et al. Characteristics of Joint Involvement and Relationships with Systemic Inflammation in Systemic Sclerosis: Results from the EULAR Scleroderma Trial and Research Group (EUSTAR) Database. J Rheumatol 2010; 37: 1488-1501. .
 
18.
Kucharz EJ, Grucka-Mamczar E, Mamczar A, et al. Acute-Phase Proteins in Patients with Systemic Sclerosis. Clin Rheumatol 2000; 19: 165-166. .
 
19.
Fagundus DM, LeRoy EC. Cytokines and systemic sclerosis. Clin Dermatol 1994; 12: 407-417.
 
Copyright: © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (https://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
eISSN:2084-9834
ISSN:0034-6233
Journals System - logo
Scroll to top